<DOC>
	<DOCNO>NCT00354822</DOCNO>
	<brief_summary>Pilot multicentre , open label study aim evaluate antitumor activity term sum complete partial response ( O.R.R . ) chemotherapy ( cyclophosphamide fludarabine ) rituximab , follow zevalin radioimmunotherapy response duration ( Time relapse progression ) evaluate safety treatment acute late toxicity . Secondary objective evaluate overall survival ( OS ) event-free survival ( EFS ) .</brief_summary>
	<brief_title>Fludarabine , Cyclophosphamide Rituximab Followed Zevalin Non-Follicular Indolent Lymphomas .</brief_title>
	<detailed_description>Test medication : - Yttrium-90 ( 90Y ) ibritumomab tiuxetan 0.4 mCi/kg deliver patient achieve least partial remission ( PR ) chemotherapy single dose patient baseline platelet count &gt; 150x10^9/L 0.3 mCi/kg patient baseline platelet count 100 149x10^9/L . Rituximab 250mg/sqm give prior therapeutic radiolabeled antibody . - Standard dose chemotherapy consist cyclophosphamide , fludarabine rituximab give every 28 day best response ( maximum 6 course ) . - A prophylaxis pneumocystis carinii well herpes zoster need treatment . Main parameter activity : activity Yttrium-90 ( 90Y ) ibritumomab tiuxetan cyclophosphamide , fludarabine rituximab combination .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients lymphoma refractory frontline chemotherapy , include fludarabine , first relapse chemotherapy include fludarabine , suitable highdose chemotherapy support auto allogeneic bone marrow transplantation . Histologicallyconfirmed small lymphocytic ( SLL ) , lymphoplasmacytic ( LPL ) marginal zone ( MZL ) lymphoma . All prior chemotherapy , include corticosteroid , complete &gt; 4 week study treatment ; &lt; 25 % active bone marrow irradiate previously ; prior bone marrow transplantation . Age : 1870 year ECOG performance status : 02 . No allergy mouse protein . CD20 positive B cell lymphoma . Ann Arbor stage III IV disease bidimensionally measurable disease least one site irradiate , include adenopathy mass could measure physical examination &gt; 5 cm compute tomographic scan ( CT ) . In event splenomegaly hepatomegaly , extension 5 cm costal margin consider evidence measurable disease . Osteoblastic bone lesion , ascites pleural effusion consider measurable disease . Tumor involvement marrow &lt; 25 % treatment Zevalin . Acceptable hematologic status within one week prior study start : Hb &gt; 9g/dL , white blood count &gt; 3x10^9/L , absolute neutrophil count &gt; 1.5x10^9/L , platelet &gt; 100x10^9/L . Written inform consent prior study specific screening procedure , understand patient right withdraw study time , without prejudice . Patients willing able comply protocol duration study . Patients , sexually active , must agree use effective contraception entire treatment period 1 year follow treatment . Women , childbearing potential , must negative pregnancy test . Histologies include History malignancy squamous cell carcinoma , basal cell carcinoma skin carcinoma situ cervix within last 5 year . Major surgery , diagnostic surgery , within last 4 week . Presence malignant ascites pleural effusion . Evidence CNS involvement . Patients history uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant adversely affect compliance study drug . Clinically significant cardiac disease ( e.g . congestive heart failure , symptomatic coronary artery disease , cardiac arrhythmia well control medication , myocardial infarction within last 6 month , NYHA class III IV heart disease ) , abnormal liver function test , disease relate , within 1 week prior study start ( serum bilirubin &gt; 2 mg/dL ; ALAT &gt; 2.5 x upper normal limit ; alkaline phosphatase &gt; 2.5xupper normal limit ) , abnormal renal function , disease relate ( serum creatinine &gt; 2.0 mg/dL ) , active opportunistic infection . Serum positivity HIV , HBsAg HCV except sign active viral replication , assess HCVRNA HBVDNA . This latter group patient enrol study , receive lamivudine prophylaxis bimonthly evaluation HbSAg , HbCAb HBVDNA provide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Zevalin</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
</DOC>